State of the art in the treatment of Hodgkin lymphoma

被引:57
作者
Borchmann, Peter [1 ]
Eichenauer, Dennis A. [1 ]
Engert, Andreas [1 ]
机构
[1] Univ Hosp Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
关键词
INVOLVED-FIELD RADIOTHERAPY; STEM-CELL TRANSPLANTATION; POSITRON-EMISSION-TOMOGRAPHY; ELDERLY-PATIENTS; RETROSPECTIVE ANALYSIS; NODE RADIOTHERAPY; RANDOMIZED-TRIAL; PROGNOSTIC SCORE; LIMITED-STAGE; STANFORD-V;
D O I
10.1038/nrclinonc.2012.91
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hodgkin lymphoma (HL) has become one of the most easily curable malignancies in oncology. More than 80% of patients can be cured with risk-adapted treatment that includes chemotherapy and radiotherapy. This progress is mainly due to the development of multi-agent chemotherapy and improved radiation techniques; however, severe, life-threatening treatment-related side effects occur, which include organ toxicity and secondary malignancies. Thus, the treatment approaches must be carefully balanced between optimal disease control and the risk of long-term sequelae. Although this article is meant to provide an overview of the current treatment approaches for patients with HL, in many instances conflicting results from various clinical trials are available, and a personal judgment is inevitable. Here, we focus on evidence from large clinical trials with solid conclusions. Borchmann, P. et al. Nat. Rev. Clin. Oncol. 9, 450-459 (2012); published online 12 June 2012; doi:10.1038/nrclinonc.2012.91
引用
收藏
页码:450 / 459
页数:10
相关论文
共 73 条
[21]  
Eich HT, 2008, STRAHLENTHER ONKOL, V184, P406, DOI 10.1007/s00066-008-1882-7
[22]   Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial [J].
Eich, Hans Theodor ;
Diehl, Volker ;
Goergen, Helen ;
Pabst, Thomas ;
Markova, Jana ;
Debus, Juergen ;
Ho, Anthony ;
Doerken, Bernd ;
Rank, Andreas ;
Grosu, Anca-Ligia ;
Wiegel, Thomas ;
Karstens, Johann Hinrich ;
Greil, Richard ;
Willich, Normann ;
Schmidberger, Heinz ;
Doehner, Hartmut ;
Borchmann, Peter ;
Mueller-Hermelink, Hans-Konrad ;
Mueller, Rolf-Peter ;
Engert, Andreas .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4199-4206
[23]   Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial [J].
Ekstrand, BC ;
Lucas, JB ;
Horwitz, SM ;
Fan, Z ;
Breslin, S ;
Hoppe, RT ;
Natkunam, Y ;
Bartlett, NL ;
Horning, SJ .
BLOOD, 2003, 101 (11) :4285-4289
[24]   Hodgkin's lymphoma in elderly patients:: A comprehensive retrospective analysis from the German Hodgkin's Study Group [J].
Engert, A ;
Ballova, V ;
Haverkamp, H ;
Pfistner, B ;
Josting, A ;
Dühmke, E ;
Müller-Hermelink, K ;
Diehl, V .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5052-5060
[25]  
Engert A., LANCET
[26]   Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma:: Final results of the GHSG HD7 trial [J].
Engert, Andreas ;
Franklin, Jeremy ;
Eich, Hans Theodor ;
Brillant, Corinne ;
Sehlen, Susanne ;
Cartoni, Claudio ;
Herrmann, Richard ;
Pfreundschuh, Michael ;
Sieber, Markus ;
Tesch, Hans ;
Franke, Astrid ;
Koch, Peter ;
de Wit, Maike ;
Paulus, Ursula ;
Hasenclever, Dirk ;
Loeffler, Markus ;
Mueller, Rolf-Peter ;
Mueller-Hermelink, Hans Konrad ;
Duehmke, Eckhart ;
Diehl, Volker .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) :3495-3502
[27]   Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma [J].
Engert, Andreas ;
Pluetschow, Annette ;
Eich, Hans Theodor ;
Lohri, Andreas ;
Doerken, Bernd ;
Borchmann, Peter ;
Berger, Bernhard ;
Greil, Richard ;
Willborn, Kay C. ;
Wilhelm, Martin ;
Debus, Juergen ;
Eble, Michael J. ;
Soekler, Martin ;
Ho, Antony ;
Rank, Andreas ;
Ganser, Arnold ;
Truemper, Lorenz ;
Bokemeyer, Carsten ;
Kirchner, Hartmut ;
Schubert, Joerg ;
Kral, Zdenek ;
Fuchs, Michael ;
Mueller-Hermelink, Hans-Konrad ;
Mueller, Rolf-Peter ;
Diehl, Volker .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (07) :640-652
[28]   Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study [J].
Engert, Andreas ;
Diehl, Volker ;
Franklin, Jeremy ;
Lohri, Andreas ;
Doerken, Bernd ;
Ludwig, Wolf-Dieter ;
Koch, Peter ;
Haenel, Mathias ;
Pfreundschuh, Michael ;
Wilhelm, Martin ;
Truemper, Lorenz ;
Aulitzky, Walter-Erich ;
Bentz, Martin ;
Rummel, Mathias ;
Sezer, Orhan ;
Mueller-Hermelink, Hans-Konrad ;
Hasenclever, Dirk ;
Loeffler, Markus .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) :4548-4554
[29]   ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial [J].
Federico, Massimo ;
Luminari, Stefano ;
Iannitto, Emilio ;
Polimeno, Giuseppe ;
Marcheselli, Luigi ;
Montanini, Antonella ;
La Sala, Antonio ;
Merli, Francesco ;
Stelitano, Caterina ;
Pozzi, Samantha ;
Scalone, Renato ;
Di Renzo, Nicola ;
Musto, Pellegrino ;
Baldini, Luca ;
Cervetti, Giulia ;
Angrilli, Francesco ;
Mazza, Patrizio ;
Brugiatelli, Maura ;
Gobbi, Paolo G. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :805-811
[30]   Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease [J].
Ferme, Christophe ;
Eghbali, Houchingue ;
Meerwaldt, Jacobus H. ;
Rieux, Chantal ;
Bosq, Jacques ;
Berger, Francoise ;
Girinsky, Theodore ;
Brice, Pauline ;
van't Veer, Mars B. ;
Walewski, Jan A. ;
Lederlin, Pierre ;
Tirelli, Umberto ;
Carde, Patrice ;
Van den Neste, Eric ;
Gyan, Emmanuel ;
Monconduit, Mathieu ;
Divine, Marine ;
Raemaekers, John M. M. ;
Salles, Gilles ;
Noordijk, Evert M. ;
Creemers, Geert-Jan ;
Gabarre, Jean ;
Hagenbeek, Anton ;
Reman, Oumedaly ;
Blanc, Michel ;
Thomas, Jose ;
Vie, Brigitte ;
Kluin-Nelemans, Johanna C. ;
Viseu, Fernando ;
Baars, Joke W. ;
Poortmans, Philip ;
Lugtenburg, Pieternella J. ;
Carrie, Christian ;
Jaubert, Jerome ;
Henry-Amar, Michel .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (19) :1916-1927